Search Results

Dyne Therapeutics, Inc today announced new preclinical data in a Pompe disease model demonstrating the potential of the FORCE™ platform to deliver enzyme replacement therapy to cardiac and skeletal muscle and the central nervous system (CNS).

Dyne Therapeutics, Inc., a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, highlighted new preclinical data for DYNE-302, its product candidate for facioscapulohumeral muscular dystrophy, that demonstrated robust and durable DUX4 suppression and functional benefit.